GfK enhances Therapeutic Class DynamicsTM physician studies program beyond U.S. and EU to include insights across Brazil, Russia, India, China
NUREMBERG -- (BUSINESS WIRE) --
Recognizing pharmaceutical manufacturers' expanding needs for cost-effective syndicated research insights to support market assessment and brand strategy in the growing BRIC markets, GfK HealthCare announced it will build upon its long-standing U.S. syndicated offering, Therapeutic Class DynamicsTM (TCD) physician studies, to offer further local market treatment perspectives. The new studies cover Brazil, Russia, India and China and include detailed perspectives across several indications within cardiovascular, psychiatry, respiratory and rheumatology/pain.
Serving as a foundation for the new BRIC offering, GfK has produced TCD studies in the U.S. for more than 45 years across a broad number of therapeutic categories; more recently, the syndicated program was expanded to cover the Top 5 EU markets (France, Germany, Italy, Spain and the United Kingdom). Now, in response to growing client demand for insights into the emerging markets, TCD will capture physician perspectives across BRIC - as well as Japan - in 2012.
TCD studies provide brand teams with detailed perspectives from key prescribers, encompassing insights on patient volume, prescribing and switching behavior, unmet market needs, competitive strengths and weaknesses, as well as physician perceptions, attitudes and actions. The insights are used to inform a wide range of business challenges, including the development of branding and competitive strategies, evaluation of merger and co-promotion opportunities, assessment of new compounds and other development options, as well as to help understand perceptual changes together with their drivers and to develop targeted messages.
GfK's move to expand its syndicated research program into the BRIC markets is a natural extension of its in-depth understanding of these local markets and health care systems, as captured through the company's extensive experience conducting custom research across these and other emerging regions. GfK maintains local offices in all four BRIC markets, as part of its presence across more than 100 countries.
"Now, more than ever, our clients are seeking ways they can obtain the depth of information they require to support a number of critical business decisions, in a limited amount of time - and with a limited budget," said Heinz Ohde, manager, global syndicated services, GfK HealthCare. "Using a multiclient approach, together with the efficiency of online research, we are able to use TCD to deliver deep local market insights into therapeutic areas at a reasonable cost; our expansion of TCD into Europe and now the BRIC markets and Japan speaks to the value these studies have created for dozens of global pharmaceutical companies."
About GfK HealthCare
GfK HealthCare (www.gfkhc.com) is the largest provider of fully integrated custom health care marketing research in the world, with the broadest range of custom and syndicated research offerings as well as innovative proprietary approaches to meet a product's needs across its life cycle. GfK HealthCare is part of the Custom Research sector within the GfK Group (www.gfk.com), which offers the fundamental knowledge that industry, retailers, services companies and the media need to make market decisions. GfK delivers a comprehensive range of information and consultancy services in the three business sectors of Custom Research, Retail and Technology and Media. The No. 4 market research organization worldwide operates in more than 100 countries and employs over 11,000 staff. In 2010, the GfK Group's sales amounted to EUR 1.29 billion.
CONTACT:
GfK HealthCare
Jessica Makovsky
VP Global Communications
+1-267-304-3780
jessica.makovsky@gfk.com